

Achim Rittmeyer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4923903/achim-rittmeier-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

6,509
citations

17
h-index

42
g-index

42
ext. papers

8,505
ext. citations

7.3
avg, IF

5.22
L-index

#	Paper	IF	Citations
38	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel 2021 , 9,		4
37	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2021 ,	4.9	2
36	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3093-3105	4.4	2
35	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021 , 152, 174-184	5.9	21
34	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 140-150	8.9	32
33	Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). <i>Lung Cancer</i> , 2021 , 160, 17-27	5.9	1
32	Top-level gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. <i>Translational Lung Cancer Research</i> , 2020 , 9, 603-616	4.4	8
31	Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. <i>Clinical Medicine Insights: Oncology</i> , 2020 , 14, 1179554920951358	1.8	8
30	Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , 2019 , 22, 68-73	0	
29	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. <i>Immunotherapy</i> , 2019 , 11, 769-782	3.8	6
28	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 924-937	21.7	562
27	Abscopal effect in lung cancer: three case reports and a concise review. <i>Immunotherapy</i> , 2019 , 11, 1445-1461	3.6	21
26	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019 , 25, 64-72	12.9	96
25	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019 , 128, 105-112	5.9	77
24	Multidisciplinary treatment of lung cancer in older patients: A review. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 405-410	3.6	11
23	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. <i>Clinical Cancer Research</i> , 2018 , 24, 3292-3298	12.9	22
22	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <i>Nature Medicine</i> , 2018 , 24, 1441-1448	50.5	581

21	Medikamentöse Therapie des metastasierten oder rezidivierten mutationsnegativen NSCLC. <i>Onkologe</i> , 2018 , 24, 1003-1008	0.1	0
20	Immuntherapien beim fortgeschrittenen NSCLC. <i>Tumor Diagnostik Und Therapie</i> , 2018 , 39, 371-384	0.1	
19	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1906-1918	8.9	50
18	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 441-449.e4	4.9	42
17	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1156-1170	8.9	134
16	Prospects and progress of atezolizumab in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 781-789	5.4	11
15	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 255-265	4.0	2681
14	Treatment of limited disease small cell lung cancer: the multidisciplinary team. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	13
13	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 43-49	4.9	23
12	Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial. <i>OncoTargets and Therapy</i> , 2017 , 10, 1081-1089	4.4	14
11	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9001-9001	2.2	14
10	Chemotherapie beim älteren Patienten mit nicht kleinzelligem Lungenkarzinom: Eine nichtinterventionelle, prospektive, multizentrische Beobachtungsstudie. <i>Tumor Diagnostik Und Therapie</i> , 2017 , 38, 634-640	0.1	
9	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1837-46	4.0	1731
8	Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9028-9028	2.2	15
7	Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9032-9032	2.2	14
6	Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 2208-2217	8.9	32
5	Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. <i>Cancers</i> , 2015 , 7, 950-62	6.6	4
4	Reply to B.M. Strebel. <i>Journal of Clinical Oncology</i> , 2014 , 32, 479-80	2.2	

3	Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). <i>Journal of Clinical Oncology</i> , 2013 , 31, 3004-11	2.2	243
2	Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1409-16	8.9	20
1	Smoking cessation in lung cancer-achievable and effective. <i>Deutsches A&#x0308;rztblatt International</i> , 2013 , 110, 719-24	2.5	14